Science & Technology
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AR083781-01
Award Ceiling
$295K
Award Floor
$295K
Close Date
Aug 31, 2024
Total Funding
$295K
Expected Awards
1
Posted Date
Sep 20, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AR083781-01
Description
SBIR Phase Phase I award: "Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne." awarded to DERMAXON LLC in MISSOULA, Montana. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $295,423. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.